Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
NCT ID: NCT01501708
Last Updated: 2016-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
55 participants
INTERVENTIONAL
2011-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Escalation Antifungal Prophylaxis for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT04273178
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
NCT01232504
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation
NCT00148148
Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
NCT01040156
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
NCT06698211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caspofugin based combination therapy
Caspofugin based combination therapy:
Patients will recieve caspofungin with voriconazole or amphotericin B
Caspofugin based combination therapy
Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d.
* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.
* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caspofugin based combination therapy
Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d.
* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.
* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-55 years
* with inform consent
* no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
* HLA mismatched related (3\~5/6) or unrelated donors (at least 8/10)
* proven or probable IFI
Exclusion Criteria
* HLA mismatched related donor
* liver function/renal function damage (over 2 X upper normal range)
* with mental disease
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiong HU
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ling Wang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ling Wang, M.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RJH-2011-71
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.